Showing 1179 results
- https://www.novartis.com/news/media-releases/novartis-fokussiert-ihre-division-pharmaceuticals-durch-schaffung-der-geschaftseinheiten-novartis-pharmaceuticals-und-novartis-oncology-und-beruft-deren-leiter-die-geschaftsleitung-von-novartisPaul Hudson wird zum CEO, Novartis Pharmaceuticals, und Bruno Strigini zum CEO, Novartis Oncology, ernannt; David Epstein wird Novartis verlassen Paul Hudson und Bruno Strigini werden in…
- https://www.novartis.com/news/media-releases/novartis-foundation-and-partners-launch-innovative-hypertension-program-vietnamHo Chi Minh City Communities for Healthy Hearts Program is the second innovative healthcare model for hypertension pioneered by the Novartis Foundation Screening and treatment shifts to the…
- https://www.novartis.com/news/media-releases/major-study-published-nejm-confirms-novartis-ultibro-breezhaler-superiority-over-seretide-preventing-copd-exacerbationsFLAME study showed consistent superiority of Ultibro® Breezhaler® over Seretide® across exacerbation outcomes, lung function and health-related quality of life in COPD patients Ultibro…
- https://www.novartis.com/news/media-releases/novartis-drug-afinitor-recommended-chmp-european-union-approval-treat-select-gi-and-lung-neuroendocrine-tumorsIf approved, Afinitor would be first treatment in EU indicated for advanced progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Advanced, progressive, nonfunctional…
- https://www.novartis.com/news/media-releases/novartis-kisqali-reduced-risk-cancer-recurrence-while-maintaining-quality-life-patients-diagnosed-early-breast-cancerPatient-reported outcomes (PROs) from the Phase III NATALEE trial show that patients receiving adjuvant Kisqali plus endocrine therapy (ET) for up to three years maintained physical and social…
- https://www.novartis.com/news/media-releases/novartis-receives-three-fda-breakthrough-therapy-designations-ilaris-treat-rare-types-periodic-fever-syndromesSubject to approvals, Ilaris® will likely be first FDA-approved treatment for TRAPS and HIDS/MKD, and an important alternative treatment for patients with FMF Designations support potential…
- https://www.novartis.com/news/media-releases/novartis-delivered-solid-q1-despite-gleevec-loss-exclusivity-investing-behind-new-launches-long-term-growthNet sales up 1% (cc[1]), as Growth Products offset Gleevec impact Growth Products[2] grew 24% (USD) to USD 3.9 billion, or 34% of Group net sales Cosentyx (USD 176 million) continues to grow…
- https://www.novartis.com/news/media-releases/novartis-shareholders-approve-proposed-100-spin-sandozShareholders approve the proposed 100% Spin-off of Sandoz, the Generics and Biosimilars business of NovartisShareholders also approve a reduction of share capital in connection with the Spin-off…
- https://www.novartis.com/news/media-releases/les-actionnaires-de-novartis-approuvent-le-projet-de-scission-100-de-sandozLes actionnaires approuvent le projet de scission à 100% de Sandoz, l’activité Génériques et Biosimilaires de NovartisLes actionnaires approuvent également une réduction du capital social dans le…
- https://www.novartis.com/news/media-releases/aktionarinnen-und-aktionare-von-novartis-stimmen-dem-geplanten-100-igen-spin-von-sandoz-zuDie Aktionärinnen und Aktionäre stimmen dem geplanten 100%igen Spin-off von Sandoz, dem Generika- und Biosimilars-Geschäft von Novartis, zu.Die Aktionärinnen und Aktionäre stimmen ausserdem einer…
Pagination
- ‹ Previous page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- …
- 118
- › Next page